Supply of weight loss drug Wegovy expected to improve in next few months, company says


Wegovi, the maker of the popular weight-loss drug. Said Wednesday it is ramping up production of the drug. Which is in short supply at pharmacies across the United States.

The drug faced massive shortages . last year due to its growing popularity, executives at drugmaker Novo . Nordisk said in a call with investors on Wednesday.

Novo Nordisk said on Dec. 28 that all doses of the drug would be available again after . The supply problem, but added that it could take time for the drug to reach . Pharmacies from distribution centers.


There continues to be “pent up demand” for Wegovi, but Novo Nordisk expects that to become . less of a problem as more supplies of the drug become available in the coming months, Jorgensen said.

“We’re encouraged by . The trendline we see, but there will be a normalization of it,” he said.

Wegovi, or semaglutide, is part of a class of drugs called GLP-1 agonists. They mimic a hormone that helps reduce food intake and curb hunger. In clinical trials, Wegovy has been shown to reduce body  by about 15%.

The drug is expensive, costing about $1,300 per month, and insurance companies often don’t cover it.

Wegovi shortages have forced some . People in the United States to stop taking it, causing them to regain some — or all — of their weight.

Others have prescribed . Ozempic off-label for weight loss, leading to shortages of that drug. 

Doug Langa, head of Novo Nordisk’s . North American operations, noted on the call the difficulty patients . Have had in finding the drug, but added that the company is now . looking forward” to the drug becoming more available.

Leave a Reply

Your email address will not be published. Required fields are marked *